4D Molecular Therapeutics, Inc.
NASDAQ:FDMTBiotechnology
+$0.16 today
- Market cap
- $596.08M
- Beta
- 2.76
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$2.36
Volume 0.81M
Average 0.77M
Returns on capital
4D Molecular Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-27.7%
avg -2.6%
ROIC
-30.2%
avg -40.2%
ROA
-24.7%
avg -33.3%
Analysis
ROA is currently the strongest return metric at -24.7% versus its period average of -33.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
David H. Kirn | Co-Founder, President, CEO & Director | USD 1.23M | 64 | — | — |
Fariborz Kamal | Chief Technical Advisor | USD 892.87K | 63 | 178.40K | 0.34% |
Theresa Janke | Co-Founder & Chief of Staff | USD 652.32K | 51 | — | — |
Noriyuki Kasahara | Chief Scientific Advisor | USD 201.29K | 63 | 22.50K | 0.04% |
John F. Milligan | Executive Chairman | USD 150K | 65 | 75.00K | 0.14% |
Kristian Humer | CFO and Principal Financial & Accounting Officer | USD 116.25K | 50 | 0 | <0.01% |
An Song | Chief Translational Medicine Advisor | — | — | — | — |
Scott Bizily | Chief Legal Officer & Corporate Secretary | — | 54 | 8.62K | 0.02% |
Julian Pei | Head of Investor Relations & Corporate Finance | — | — | — | — |
Katy Barglow | Chief Technical Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 16, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
24
$5.34M
Net Transaction Value
−$5.34M
Net selling
Most Active
Kirn David
12 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 16, 26Oct 16, 2026 | Bizily Scott Direct | Sell | $21K$20,993.40 |
| Oct 5, 26Oct 5, 2026 | Kirn David Direct | Sell | $750.2K$750,235.21 |
| Oct 5, 26Oct 5, 2026 | Kirn David Direct | Sell | $3.7K$3,702.03 |
| Sep 16, 26Sep 16, 2026 | Bizily Scott Direct | Sell | $22.3K$22,317.75 |
| Sep 14, 26Sep 14, 2026 | Kirn David Direct | Sell | $811K$811,003.70 |
| Sep 1, 26Sep 1, 2026 | Bizily Scott Direct | Sell | $8.2K$8,176.00 |
| Aug 19, 26Aug 19, 2026 | Kirn David Direct | Sell | $662.6K$662,621.93 |
| Aug 19, 26Aug 19, 2026 | Kirn David Direct | Sell | $425.7K$425,651.34 |
| Aug 17, 26Aug 17, 2026 | Bizily Scott Direct | Sell | $19.9K$19,947.00 |
| Aug 13, 26Aug 13, 2026 | Bizily Scott Direct | Sell | $19.6K$19,620.00 |
1–10 of 24
Summary
Insiders reported 0 buys worth $0.00 and 24 sells worth $5.34M over the last 12 months. That adds up to net selling of $5.34M. Kirn David was the most active insider with 12 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +200.9% | +37.5% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +200.9% over three years. Forward estimates point to Revenue at +37.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does 4D Molecular Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about FDMT's management, answered from reported figures.
Who manages FDMT?
4D Molecular Therapeutics, Inc. (FDMT) lists 10 active executives. The top listed executive is John F. Milligan, Executive Chairman.
Are FDMT insiders buying or selling?
Recent insider activity shows net buying of $18.32M.
Continue the stock analysis
Jump to another research area for this company.